还有巴西跟那个印度还有还有那个欧盟的一些国家地区呢现在的销量也有明显的一个增长所以说国内的产能我们也会逐步的把它那个维持维持好然后美国的产能呢就是大概率在今年三季度那么八 应该是八月份差不多就开始投产我们呢目前以我们目前的一个信息量有这两百亿的产能应该很快就会打满并且我们会提前启动后续的扩产因为我们美国的工厂整个厂区的规划大概可以容纳四到五百亿也就是说我们未来未来的目标呢 占据美国市场一半以上的这个范围从目前我们实施的那个情况来看这个目标呢未来未来实现这个目标我们还是很有信心的也就是说我们很快就会成为智慧教导这个领域全球的第一超越超越农场现在四百五十亿的产能 销量也是在提升因为将来我们国内的产能那么主要也有也会靠欧洲来消化从我见两个月的那个掌握的数据呢欧洲的每个月的那个销量都接近十亿笔别 比去年又有一个大幅度的增长今年大概率欧洲会达到一百一二十一例的一个一个销量去年大概是八十一例左右今年还是一个比较大的提升这也是一个科学的变化再加上我们在欧美之外包括那个澳大利亚加拿大等等这些这些国家 呃成为智慧教能的全球的那个第一并且逐步跟第二名第三名逐步拉大距离呃呃这是这是我们可以看得见摸得着的一个呃一个目标呃最后从智慧教 ...

Group 1 - A recent incident in Fujian highlights the dangers of improperly taking medication, where a man experienced a severe drop in blood pressure after splitting a controlled-release antihypertensive tablet, leading to a medical emergency [1] - Medications labeled with "controlled-release," "sustained-release," or "enteric-coated" should be swallowed whole, as breaking or crushing them can lead to rapid drug release, potentially causing shock or death [1][2] - Controlled-release tablets are designed to release medication at a constant rate, allowing for once-daily dosing, while regular tablets require multiple doses throughout the day [2] Group 2 - Sustained-release tablets, while having a different manufacturing process than controlled-release tablets, also aim for slow drug release and should not be split, as this can lead to adverse reactions [4] - Enteric-coated tablets are designed to dissolve in the intestines rather than the stomach; splitting them can cause premature dissolution in the stomach, affecting efficacy and potentially irritating the gastric lining [4] - Capsules should not be opened, as this can expose the medication to stomach acid, affecting its release and increasing gastrointestinal side effects [4] Group 3 - Patients should be aware of the proper sequence and timing for taking medications, as this can impact their effectiveness and reduce the risk of adverse reactions [5] - It is advised to space the intake of traditional Chinese medicine and Western medicine by about half an hour, and to take certain medications after meals to minimize gastrointestinal irritation [5] - Storage conditions for medications, including temperature and humidity, are crucial for maintaining their efficacy; for example, insulin must be stored between 2°C and 8°C to remain effective [6][8]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of SIRIO PHARMA CO., LTD. 仙 樂 健 康 科 技 股 份 有 限 公 司 (A joint stock company incorporated in the People's Republic of Chin ...

Core Viewpoint - The article reports on the seizure of 2,682 pieces of "three-no" (unregistered, untested, and unapproved) weight loss pills and capsules by the Yantai Customs, highlighting the risks associated with unregulated substances and the enforcement of drug import regulations in China [1]. Group 1: Incident Details - Yantai Customs discovered suspicious items in the luggage of a traveler using the "no declaration channel" upon arrival [1]. - The traveler claimed the items were for someone else and intended for weight loss purposes [1]. - The seized products tested positive for methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA), both of which are classified as controlled substances with addictive properties [1]. Group 2: Regulatory Context - The import and export of narcotic and psychotropic drugs in China require permits issued by the National Medical Products Administration [1]. - The seized weight loss products were temporarily detained by customs in accordance with the relevant laws and regulations [1].

Core Viewpoint - The stock price of Tongchen Beijian has increased by 2.08% this year, with a market capitalization of 20.74 billion yuan as of January 5, 2025 [1][2]. Group 1: Stock Performance - As of January 5, 2025, the stock price reached 12.26 yuan per share, with a trading volume of 1.03 billion yuan and a turnover rate of 0.75% [1]. - The stock has experienced a decline of 0.89% over the last five trading days, but has increased by 3.20% over the last 20 days and 5.33% over the last 60 days [2]. Group 2: Company Overview - Tongchen Beijian, established on April 1, 2005, and listed on December 15, 2010, specializes in the research, production, and sales of dietary nutritional supplements [2]. - The company's revenue composition includes 38.02% from other products, 27.84% from capsules, 20.38% from tablets, and 13.76% from powders [2]. - The company is classified under the food and beverage industry, specifically in food processing and health products, with concepts including gene sequencing, vitamins, internet healthcare, cross-border e-commerce, and pharmaceutical e-commerce [2]. Group 3: Financial Performance - For the period from January to September 2025, Tongchen Beijian reported a revenue of 4.915 billion yuan, a year-on-year decrease of 14.27%, while the net profit attributable to shareholders increased by 4.45% to 907 million yuan [2]. - Since its A-share listing, the company has distributed a total of 8.321 billion yuan in dividends, with 2.429 billion yuan distributed over the last three years [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders is 71,100, a decrease of 0.14% from the previous period, with an average of 15,762 circulating shares per person, down by 0.67% [2]. - The second-largest circulating shareholder is E Fund's ChiNext ETF, holding 20.8508 million shares, a decrease of 3.7464 million shares from the previous period [3].

Core Viewpoint - The rise of "stem cell beauty" treatments has led to significant consumer spending and legal disputes, highlighting a broader market issue of unregulated practices and misleading claims in the beauty industry [1][21][22]. Group 1: Consumer Experiences and Financial Impact - A case study reveals that an individual spent over 20 million yuan on stem cell beauty treatments, leading to a lawsuit against the beauty clinic for unlicensed medical practices [1][22]. - The financial burden escalated over time, with reported expenditures of 300 million yuan in 2021 and 700 million yuan in 2023 for various stem cell treatments [3][23]. - Another individual reported spending nearly 4 million yuan on a single stem cell injection, only to discover that the recommending friend received a 50% kickback, raising concerns about the legitimacy of the treatments [7][25]. Group 2: Regulatory Response and Industry Standards - The National Health Commission emphasized that stem cell and gene therapies must be conducted by qualified medical institutions, prohibiting beauty salons from offering such services [21][22]. - Despite regulatory efforts, the market remains flooded with unapproved stem cell products, with many lacking legitimate scientific backing and being marketed with exaggerated claims [9][11][27]. - As of 2023, no stem cell products for beauty injections have received national approval, and the majority of clinical trials focus on serious medical conditions rather than cosmetic applications [11][31]. Group 3: Scientific and Medical Context - Stem cell technology is still in the early stages of research and requires rigorous validation before being applied in clinical settings, particularly for cosmetic purposes [10][14][33]. - The FDA has approved specific stem cell therapies for limited medical conditions, indicating a cautious approach to the commercialization of stem cell treatments [10][28]. - Experts warn against the commercialization of stem cell technology without a comprehensive understanding of its implications, stressing the need for consumer protection and regulatory oversight [15][33][36].

Core Viewpoint - The article emphasizes the dangers of taking capsule medications with hot water, highlighting that it can compromise the capsule's integrity and lead to health risks. Group 1: Capsule Characteristics - Capsules account for approximately 20% of prescriptions written by doctors, but they are sensitive to hot water [2] - Capsules are made from different materials, primarily gelatin, which is a protein product that dissolves in warm and hot water [2] - Experiments show that capsules can soften and become sticky in water at 50°C within 10 seconds [2] Group 2: Health Risks - If the capsule structure is damaged by high water temperature, the medication may not reach the intestines as intended and could irritate the gastric mucosa [6] - Some capsules are designed for slow or controlled release; premature destruction of the capsule can lead to adverse reactions [7] - Soft capsules should be stored at temperatures between 8°C and 20°C, and using hot water can cause them to stick together [8] Group 3: Recommendations for Taking Capsules - It is advised to use room temperature water and to lean forward while swallowing capsules [9][10] - A sufficient amount of water, around 200-250 milliliters, should be used to swallow capsules [12] Group 4: Other Medications Not Suitable for Hot Water - Vitamin supplements, such as Vitamin C and B vitamins, can lose efficacy when exposed to heat [16] - Digestive aids containing active enzymes, like pancreatin and yeast tablets, can denature when heated [19] - Medications containing live bacteria, such as certain probiotic capsules, should be taken with cool or warm water [20] - Cough syrups, which form a protective layer on the throat, can lose effectiveness if taken with hot water [21]

Core Viewpoint - The article emphasizes the dangers of taking capsule medications with hot water, highlighting the potential health risks associated with this practice. Group 1: Risks of Taking Capsules with Hot Water - Capsules, which account for about 20% of prescriptions, are sensitive to heat, particularly those made from gelatin, which can dissolve in warm water [3] - Exposure to water at 50°C for just 10 seconds can cause capsules to become soft and sticky, leading to potential health risks such as esophageal damage and drug release issues [3][4] - If capsules dissolve prematurely, they can cause local damage to the esophagus, especially if they contain irritating drugs like doxycycline or ibuprofen [3][4] Group 2: Recommendations for Capsule Consumption - It is advised to use room temperature water for swallowing capsules, and individuals should wait a while after taking capsules before drinking hot water [5][6] - Techniques for swallowing capsules include maintaining an upright position, moistening the throat with water before swallowing, and using a forward-leaning method to facilitate swallowing [6][7] Group 3: Other Medications Not Suitable for Hot Water - Certain medications, such as vitamin C and B vitamins, can lose efficacy when exposed to heat [11] - Digestive aids like pancreatic enzymes and yeast tablets can denature when heated, losing their effectiveness [12] - Probiotic medications should be taken with cool or warm water, as they require refrigeration and are sensitive to heat [13] - Cough syrups, which rely on viscosity for effectiveness, can have their properties altered by hot water, reducing their therapeutic effects [14]

Core Viewpoint - The stock price of Tongrentang has shown a modest increase, with a notable rise in trading volume and a positive net inflow of funds, indicating investor interest in the company [1][2]. Group 1: Stock Performance - As of December 25, Tongrentang's stock price increased by 2.08%, reaching 12.28 CNY per share, with a trading volume of 1.25 billion CNY and a market capitalization of 20.774 billion CNY [1]. - Year-to-date, the stock price has risen by 5.01%, with a 2.68% increase over the last five trading days, a 0.49% increase over the last 20 days, and a 5.05% increase over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Tongrentang reported a revenue of 4.915 billion CNY, a year-on-year decrease of 14.27%, while the net profit attributable to shareholders was 907 million CNY, reflecting a year-on-year increase of 4.45% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tongrentang was 71,100, a slight decrease of 0.14% from the previous period, with an average of 15,762 circulating shares per person, down by 0.67% [2]. - The company has distributed a total of 8.321 billion CNY in dividends since its A-share listing, with 2.429 billion CNY distributed over the last three years [3]. Group 4: Institutional Holdings - As of September 30, 2025, the second-largest circulating shareholder is E Fund's ChiNext ETF, holding 20.851 million shares, a decrease of 3.746 million shares from the previous period [3]. - Hong Kong Central Clearing Limited is the fifth-largest shareholder, increasing its holdings by 2.712 million shares to 15.086 million shares [3].

Core Insights - Gansu Dingxi City is transforming its industrial landscape by implementing a "strong industry" initiative, focusing on both traditional and emerging industries to enhance industrial output and attract investment [2][5]. Industrial Growth - As of now, Dingxi has 295 industrial enterprises above designated size, an increase of 177 since 2020, with industrial value added growing at an average annual rate of 16% during the 14th Five-Year Plan period [2][5]. - The proportion of industrial output in GDP has risen from 9% to 13% [2]. Investment and Policy Support - Dingxi High-strength Fasteners Co., Ltd. has achieved an annual production capacity exceeding 100,000 tons, ranking among the top three in the domestic market for high-end wind power fasteners, supported by over 10 million yuan in policy funding [3]. - The city has seen a significant increase in external investment, with funds rising from 20.686 billion yuan in 2020 to 73.082 billion yuan in 2024, reflecting an annual growth rate of 37.1% [5]. Agricultural and Industrial Integration - The integration of traditional agricultural products like medicinal herbs and potatoes into industrial processes is being emphasized, with companies like Gansu Fuzheng Pharmaceutical establishing standardized planting bases and connecting with thousands of farmers [6][7]. - The potato industry has seen a transformation with companies like Gansu Blue Sky Potato Industry Development Co., Ltd. creating a closed-loop ecosystem that includes supply chain finance and product diversification [8]. Green and Digital Transformation - Gansu Dongxing Jiaxin New Materials Co., Ltd. is focusing on a green aluminum alloy production chain, achieving significant energy savings and CO2 reduction [9]. - The integration of digital technologies in industries is enhancing productivity, with companies reporting a 25% increase in efficiency through automation and digital transformation [10]. Future Outlook - Dingxi aims to establish itself as a distinctive industrial hub in the Longzhong region, focusing on resilience, innovation, structural optimization, and low-carbon transformation as part of its strategic development plan [10].